The driving force behind a new microbiome therapeutics company, AsiaBiome, leading a mission to find cures for tough diseases, including IBS, Autism, Parkinson’s and Multiple Sclerosis. Jonathan helped secure for AsiaBiome exclusive rights to a network of microbiome samples and data from Asia. He also led his company into JnJ’s JLABS, Startup+Health, and secured first financial backing by 500 startups. With this support, AsiaBiome has already identified their first microbial formulation to treat IBS and have ongoing clinical research in Autism, MS, and ALS. Previously, Jonathan was a senior investment manager for a Chinese healthcare conglomerate, focusing on hospital and pharmaceutical investment projects. He is originally from California, raised by entrepreneurs, and has spent close to a decade in Beijing and Hong Kong. He is fluent in Mandarin and English.
Emerging Therapeutics Showcase:
AsiaBiome is a leading biotechnology company focused on microbiome-based therapeutics. Building Asia's first comprehensive microbiome drug discovery platform technology.
Asian Microbiome: A new Therapeutics Discovery Opportunity
Almost 90 percent of translational microbiome research is focused on the Western gut microbiome. AsiaBiome has created the first horizontally integrated microbiome discovery platform in Asia. The company has linked together a microbiota bank, clinical network, and R&D discovery platform to launch microbiome products for both the Asia and global markets.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.